These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12597906)

  • 1. IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach.
    Selleck WA; Canfield SE; Hassen WA; Meseck M; Kuzmin AI; Eisensmith RC; Chen SH; Hall SJ
    Mol Ther; 2003 Feb; 7(2):185-92. PubMed ID: 12597906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
    Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer.
    Sanford MA; Yan Y; Canfield SE; Hassan W; Selleck WA; Atkinson G; Chen SH; Hall SJ
    Hum Gene Ther; 2001 Aug; 12(12):1485-98. PubMed ID: 11506692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy.
    Sata M; Suhara T; Walsh K
    Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):309-16. PubMed ID: 10669625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system.
    Zhang S; Zeng G; Kao C; Gardner T; Sweeney C; Yang NS; Eble JN; Cheng L
    Prostate; 2002 Sep; 53(1):69-76. PubMed ID: 12210482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
    Frost PJ; Belldegrun A; Bonavida B
    Prostate; 1999 Sep; 41(1):20-30. PubMed ID: 10440872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis.
    Hyer ML; Voelkel-Johnson C; Rubinchik S; Dong J; Norris JS
    Mol Ther; 2000 Oct; 2(4):348-58. PubMed ID: 11020350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
    Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
    Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.
    Hyer ML; Sudarshan S; Schwartz DA; Hannun Y; Dong JY; Norris JS
    Cancer Gene Ther; 2003 Apr; 10(4):330-9. PubMed ID: 12679806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P; Ng CP; Belldegrun A; Bonavida B
    Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas ligand/Fas-mediated apoptosis in human coronary artery smooth muscle cells: therapeutic implications of fratricidal mode of action.
    Belanger AJ; Scaria A; Lu H; Sullivan JA; Cheng SH; Gregory RJ; Jiang C
    Cardiovasc Res; 2001 Sep; 51(4):749-61. PubMed ID: 11530108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.
    Iwasaki T; Hamano T; Saheki K; Kuroiwa T; Kataoka Y; Takemoto Y; Ogata A; Fujimoto J; Kakishita E
    Immunology; 2000 Jan; 99(1):94-100. PubMed ID: 10651946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
    Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential involvement of the Fas receptor/ligand system in p53-dependent apoptosis in human prostate cancer cells.
    Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
    Prostate; 2000 Dec; 45(4):341-9. PubMed ID: 11102960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
    Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
    Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.
    Shariat SF; Desai S; Song W; Khan T; Zhao J; Nguyen C; Foster BA; Greenberg N; Spencer DM; Slawin KM
    Cancer Res; 2001 Mar; 61(6):2562-71. PubMed ID: 11289132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lung prevents bleomycin-induced pulmonary fibrosis via a Fas-Fas ligand-independent pathway.
    Tsuburai T; Suzuki M; Nagashima Y; Suzuki S; Inoue S; Hasiba T; Ueda A; Ikehara K; Matsuse T; Ishigatsubo Y
    Hum Gene Ther; 2002 Nov; 13(16):1945-60. PubMed ID: 12449100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.
    Roth E; Pircher H
    J Immunol; 2004 Feb; 172(3):1588-94. PubMed ID: 14734739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.